Objective: Gabapentinoid effects on sleep quality in patients with neuropathic pain have been evaluated in this study using the PSQI (Pittsburgh Sleep Quality Index). Material and Methods: A total of 450 patients with a neuropathic pain diagnosis were selected. After a medical professional diagnosed the patients with neuropathic pain, they were given a detailed description of the study's approach and asked for their informed consent. Subjects who fit the inclusion and exclusion criteria and are willing to participate in the study. During Visit-01, the demographic baseline assessment and PSQI score were finished. Patients started receiving Gabapentinoid after Visit-01. The patient was being followed up on after four weeks had passed since the enrollment date. Four weeks later, the PSQI score was assessed. After examining the PSQI Questioner and Informed Consent form, the Independent Ethics Committee (IEC) gave its approval. Data was assessed statistically using SPSS (p < 0.05).